Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.56 |
| ▸ | DRD2 | P14416 | 9/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156373 | 0.96 | DRD4 (0.56) | DRD4DRD2CACNA1HHTR1AMEN1 | |
| SCHEMBL8135888 | 0.94 | DRD4 (0.55) | DRD4DRD2CACNA1HHTR1AMEN1 | |
| SCHEMBL21017165 | 0.87 | DRD4 (0.58) | DRD4DRD2CACNA1HHTR1AKCNH2 | |
| SCHEMBL2698834 | 0.84 | LMNA (0.62) | DRD4DRD2CACNA1HCA12CA1 | |
| SCHEMBL8404323 | 0.84 | MEN1 (0.55) | DRD4DRD2CACNA1HHTR1AMEN1 | |
| SCHEMBL15248910 | 0.84 | DRD4 (0.57) | DRD4DRD2CACNA1HALDH1A1LMNA | |
| SCHEMBL19658766 | 0.82 | DRD4 (0.51) | DRD4DRD2CACNA1HHTR1AKCNH2 | |
| SCHEMBL13874787 | 0.82 | DRD4 (0.54) | DRD4DRD2CACNA1HHTR1AKCNH2 | |
| SCHEMBL21244056 | 0.81 | CA12 (0.50) | DRD4DRD2MEN1KMT2ACA12 | |
| SCHEMBL10721796 | 0.81 | DRD4 (0.65) | DRD4DRD2CACNA1HALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | DRD4 4862/4885DRD2 4815/4885CACNA1H 4834/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | DRD4 4500/4885DRD2 3681/4885CACNA1H 4832/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | DRD4 4604/4885DRD2 4507/4885CACNA1H 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.